Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michele Carbonell-Smith

Nurse Practitioner Paducah, KY Nurse Practitioner

NPI 1447557160 CMS profile 10576563

546 Lone Oak Rd, Paducah, KY 42003

Open in the dashboard

General payments

$13,290

637 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michele Carbonell-Smith of Paducah, KY is reported in the CMS Open Payments database as having received $13,290 across 637 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,946 141
2024 General $2,879 135
2023 General $2,926 132
2022 General $2,287 118
2021 General $2,252 111

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michele Carbonell-Smith
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Michele Carbonell-Smith were reported at $2,946. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Michele Carbonell-Smith Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,252 $135 $40–$426 $132
2022 $2,287 $152 $48–$470 $149
2023 $2,926 $166 $54–$529 $160
2024 $2,879 $173 $55–$556 $164
2025 $2,946 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $3,001 88 payments
  2. GlaxoSmithKline, LLC. $1,743 121 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,350 62 payments
  4. Insmed, Inc. $779 41 payments
  5. Regeneron Healthcare Solutions, Inc. $636 34 payments
  6. Genzyme Corporation $589 34 payments
  7. Actelion Pharmaceuticals US, Inc. $556 25 payments
  8. Electromed, Inc. $512 25 payments
  9. Grifols USA, LLC $465 30 payments
  10. United Therapeutics Corporation $439 21 payments
  11. Other $3,219 156 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,107 634 payments
  2. Education $183 3 payments
Products named General payments · program years 2021–2025
  1. FASENRA $1,512 41 payments
  2. BREZTRI $1,133 17 payments
  3. TEZSPIRE $927 23 payments
  4. TRELEGY ELLIPTA $849 60 payments
  5. AIRSUPRA $816 7 payments
  6. NUCALA $776 51 payments
  7. Arikayce $742 39 payments
  8. DUPIXENT Immunology $589 34 payments
  9. DUPIXENT Inflammation And Immunology $534 29 payments
  10. YUPELRI $500 31 payments
  11. Other $7,732 384 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

2,077

Median for Nurse Practitioner: 389

Drug cost

$802,746

Median for Nurse Practitioner: $21,885

Branded share of claims

72.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 315 $250,502
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 140 $123,029
Tezspire Tezepelumab-Ekko Brand 23 $97,931
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 131 $72,912
Spiriva Respimat Tiotropium Bromide Brand 83 $64,543
Airsupra Albuterol Sulfate/Budesonide Brand 48 $32,017
Arnuity Ellipta Fluticasone Furoate Brand 77 $26,359
Breo Ellipta Fluticasone/Vilanterol Brand 48 $25,483
Symbicort Budesonide/Formoterol Fumarate Brand 46 $16,739
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 29 $15,736

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$35,518

Of which drugs: $4,574

Medicare patients

212

Average age 74

Services billed

1,862

123 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 75%
Arthritis 54%
Ischemic heart disease 48%
Chronic kidney disease 40%
Diabetes 37%
Heart failure 34%
Depression 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 12 12 $3,468
Vaccine for influenza for injection into muscle 90662 Office 12 12 $982
Injection, methylprednisolone acetate, 1 mg J1010 Office 13 1,240 $124

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $269
$269 48 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $146
  • GENZYME CORPORATION $108
$254 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $234
$234 140 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $207
$207 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $99
  • Amgen Inc. $78
$177 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

637 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record